Enzymatic vitrectomy by intravitreal autologous plasmin injection, as initial treatment for diffuse diabetic macular edema;Vitrectomía enzimática por inyección intravítrea de plasmina autóloga como tratamiento inicial del edema macular diabético difuso

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 83, Issue 2, 2008, Pages 77-84

  Díaz Llopis, Manuel ^a,c   Udaondo, P ^b   Garcia Delpech S ^b   Cervera, E ^a   Salom, D ^b   Quijada, A ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Hospital Geneneral Universitario   (Spain)

^c NONE   (Spain)

Author keywords

Autologous plasmin; Diabetic macular edema; Enzimatic vitrectomy; Pharmacologic vitreolysis

Indexed keywords

PLASMIN;

AGED; ARTICLE; COMPARATIVE STUDY; DIABETIC RETINOPATHY; FEMALE; HUMAN; INJECTION; MALE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; RETINA MACULA EDEMA; VITRECTOMY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMIN; PROSPECTIVE STUDIES; VITRECTOMY; VITREOUS BODY;

EID: 41549095846     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Klein R, Klein BE, Moss SE. Visual impairment in diabetes. Ophthalmology 1984; 91: 1-9.
2. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985; 103: 1796-1806.
3. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-225.
4. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-927.
5. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999-1005.
6. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15: 508-518.
7. Lang GE. Pharmacological treatment of diabetic retinopathy. Ophthalmologica 2007; 221: 112-117.
8. Schepens CL, Avila MP, Jalkh AE, Trempe CL. Role of the vitreous in cystoid macular edema. Surv Ophthalmol 1984; 28: 499-504.
9. Ikeda T, Sato K, Katano T, Hayashi Y. Attached posterior hyaloid membrane and the pathogenesis of honeycombed cystoid macular edema in patients with diabetes. Am J Ophthalmol 1999; 127: 478-479.
10. Tachi N, Ogino N. Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol 1996; 122: 258-260.
11. Yamamoto T, Akabane N, Takeuchi S. Vitrectomy for diabetic macular edema: The role of posterior vitreous detachment and epimacular membrane. Am J Ophthalmol 2001; 132: 369-377.
12. Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H, et al. Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol 2003; 135: 14-19.
13. Gandofer A, Putz E, Welge-Lüssen U, Grüterich M, Ulbig M, Kampik A. Ultrastructure of the vitreoretinal interface following plasmin assisted vitrectomy. Br J Ophthalmol 2001; 85: 6-10.
14. Asami T, Terasaki H, Kachi S, Nakamura M, Yamamura K, Nabeshima T, et al. Ultrastructure of internal limiting membrane removed during plasmin-assisted vitrectomy from eyes with diabetic macular edema. Ophthalmology 2004; 111: 231-237.
15. Li X, Shi X, Fan J. Posterior vitreous detachment with plasmin in the isolated human eye. Graefes Arch Clin Exp Ophthalmol 2002; 240: 56-62.
16. Tanaka M, Qui H. Pharmacological vitrectomy. Semin Ophthalmol 2000; 15: 51-61.
17. Azzolini C, D'Angelo A, Maestranzi G, Codenotti M, Della Valle P, Prati M, et al. Intrasurgical plasmin enzyme in diabetic macular edema. Am J Ophthalmol 2004; 138: 560-566.
18. Sakuma T, Takana M, Inoue M, Mizota A, Souri M, Ichinose A. Efficacy of autologous plasmin for idiopathic macular hole surgery. Eur J Ophthalmol 2005; 15: 787-794.
19. Williams JG, Trese MT, Williams GA, Hartzer MK. Autologous plasmin enzyme in the surgical management of diabetic retinopathy. Ophthalmology 2001; 108: 1902-1905.
20. Rizzo S, Pellegrini G, Benocci F, Belting C, Baicchi M, Vispi M. Autologous plasmin for pharmacologic vitreolysis prepared 1 hour before surgery. Retina 2006; 26: 792-796.
21. Margherio AR, Margherio RR, Hartzer M, Trese MT, Williams GA, Ferrone PJ. Plasmin enzyme-assisted vitrectomy in traumatic pediatric macular holes. Ophthalmology 1998; 105: 1617-1620.
22. Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lüssen U, Kampik A, et al. Posterior vitreous detachment induced by microplasmin. Invest Ophthalmol Vis Sci 2004; 45: 641-647.
23. Massin P, Vicaut E, Haouchine B, Erginay A, Paques M, Gaudric A. Reproducibility of retinal mapping using optical coherence tomography. Arch Ophthalmol 2001; 119: 1135-1142.
24. Wang F, Wang Z, Sun X, Wang F, Xu X, Zhang X. Safety and efficacy of dispase and plasmin in pharmacologic vitreolysis. Invest Ophthalmol Vis Sci 2004; 45: 3286-3290.
25. Gandorfer A. Pharmacologic vitreolysis. Dev Ophthalmol 2007; 39: 149-156.
26. Trese MT. Enzymatic vitreous surgery. Semin Ophthalmol 2000; 15: 116-121.
27. Hermel M, Mahgoub M, Youssef T, Azrak MI, Raza H, Alldredge C, et al. Safety profile of the intravitreal streptokinase-plasmin complex as an adjunct to vitrectomy in the rabbit. Graefes Arch Clin Exp Ophthalmol 2006; 244: 996-1002.